ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
85 hedge funds and large institutions have $426M invested in Adaptimmune Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 33 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
48% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 33
Holders
85
Holding in Top 10
1
Calls
$725K
Puts
$429K
Top Buyers
| 1 | +$7.16M | |
| 2 | +$3.49M | |
| 3 | +$1.83M | |
| 4 |
Renaissance Technologies
New York
|
+$1.6M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$511K |
Top Sellers
| 1 | -$4.51M | |
| 2 | -$4.37M | |
| 3 | -$3.7M | |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.81M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.5M |